Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: Differences by transmission category

AIDS

Volumn 17, Issue 3, 2003, Pages 353-359

  Pérez Hoyos, Santiago ^a   Del Amo, Julia ^b,d   Muga, Roberto ^e   Del Romero, Jorge ^c   García De Olalla, Patricia ^f   Guerrero, Rafael ^g   Hernàndez Aguado, Ildefonso ^d   Ferreros, Inmaculada ^h   Cayla, Joan ^h   Brugal, Teresa ^h   Garcia De La Hera, Manoli ^h   Hurtado, Isabel ^h   Gonzàlez Aracil, Julian ^h   Aviñó, M José ^h   Muga, Robert ^e   Sanvicens, Arantza ^e   Clotet, Bonaventura ^e   Tor, Jordi ^e   Rodríguez, Carmen ^h   Díez, Mercedes ^h   García, Soledad ^h   Soriano, Vicente ^h   Marco, Andrés ^h   Quintana, Manolo ^h   Barrasa, Alicia ^h   Ruiz, Isabel ^h   Tussell, Joan ^h   Perez, Rosario ^h   Cisneros, José Miguel ^h   Castilla, Jesús ^h   more..

^a Generalitat Valenciana   (Spain)

^b Secretaria del Plan Nacional sobre el Sida   (Spain)

^c Centre for Health   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f Municipal Institute of Public Health (IMSP)   (Spain)

^g Red Penitentiary of Catalonia   (Spain)

^h Valencian Sch Hlth Studs ^*

Author keywords

Gender; HAART; Highly active antiretroviral therapy; HIV progression; Population effectiveness; Seroconverters

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG USE; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PRIORITY JOURNAL; SEROCONVERSION; SEXUAL BEHAVIOR; SPAIN; STATISTICAL SIGNIFICANCE; TIME; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SPAIN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037436185     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200302140-00009     Document Type: Article

References (38)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter L, Currier J, et al. A controlled trial of two nucleosides analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997, 337:723-733.
2. Gulick RM, Mellors JW, Havilir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Bartlett JA, Demasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001, 15:1369-1377.
4. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br Med J 1997, 315:1194-1199.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sattern GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 2001, 338:853-860.
6. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
7. Moore R, Chaisson E. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13: 1933-1942.
8. Pezzoti P, Pappagallo M, Philips AN, Boros S, Valdarchi C, Sinicco A, et al. Response to highly active antiretroviral therapy according to duration of HIV infection. J AIDS 2001, 26:473-479.
9. Philips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection. AIDS 1999, 13:2075-2082.
10. Muñoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000, 14:754-756.
11. Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001, 154:675-681.
12. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. J Am Med Assoc 1998, 280:1497-1503.
13. Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002, 155:760-770.
14. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV infection. Lancet 2000, 355:1158-1159.
15. Plan Nacional del Sida. Ministerio de Sanidad. Vigilancia epidemiológica del Sida en España. Registro nacional de casos de Sida. Balance de la epidemia a 30 de junio de 2001. Informe Semestral 1, 2001. www.msc/sida.es
16. Castilla J, Gutierrez A, Sanchez MF. Marked impact of the expanded AIDS case definition in Spain. AIDS 1994, 8:1632-1633.
17. GEMES. El período de incubación del sida en España antes de la terapia antiretroviral de alta eficacia. Med Clin (Barc.) 2000, 115:681-686.
18. Pérez-Hoyos S, Aviñó M, Hernàndez-Aguado I, Gonzalez J, Ruiz I. Tiempo libre de SIDA y supervivencia de una cohorte de usuarios de drogas por via parenteral seroconvertores frente al VIH. Gac Sanit 1999, 13:337-345.
19. Del Amo J, Del Romero J, Barrasa A, Pérez-Hoyos S, Rodríguez C, Díez M and the Grupo de Seroconvertores de la Comunidad de Madrid. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect 2002, 78:255-260.
20. Muga R, Egea JM, Navio M, Sirera G, Vall M, Tor J. Mortalidad en una cohorte de usuarios de drogas pot vía intraveonsa antes de la introducción de la terapia VIH potente. Med Clin (Barc.) 1999, 112:721-275.
21. Brugal MT, Mestres M, Díaz de Quijano E, Garcia de Olalla P, Caylá J. Evolución temporal y factores asociados a la seroconversión por HIV en una cohorte de ususarios de drogas. Rev Esp Salud Publ 1998, 72(Suppl.):142-143.
22. Caylá J, Humet V, Mangués J, Varoucha C, Quintero S, and Grupo de Estudio de Seroconversión del VIH en prisiones de Barcelona. Variables asociadas a la seroconversión del VIH en prisiones de Barcelona (España). IV Conferencia Internacional sobre la atención extrahospitalaria y comunitaria de personas que Viven con VIH/SIda. Paris, 1999.
23. Barrasa A, Castilla J, Pereira J, Herrera D, Martínez-Navarro F. Completeness of AIDS reporting in Spain: comparison with mortality data. Gac Sanit 2001, 15:482-489.
24. Ajdacic-Gross V, Zelleweger U, Wang J, Fleerackers Y, Somani B. How complete is AIDS surveillance in Europe? An eagle eye comparison with mortality data. J Epidemiol Community Health 2001, 55:52-56.
25. Plan Nacional del Sida.Ministerio de Sanidad. Encuesta hospitalaria sobre la utilización de recursos y caracterísitas de los pacientes VIH/SIDA. www.msc.es/sida/epidemiologia 1998
26. Collaborative Group on AIDS Incubation and HIV survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000, 355:1131-1137.
27. Dorrucci M, Balducci M, Pezzotti P, Sinicco A, Alberici F, Rezza G for the Italian HIV Seroconversion Study. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study. J Acquir Immune Defic Syndr 1999, 22:65-70.
28. Hubert JB, Rouzioux C, Boufassa F, et al. Gender, disease progression and response to HAART. XIV International Conference on AIDS. Barcelona July 2002 [abstract ThOrC1448].
29. Prins M, Robertson JR, Brettle RP, Aguado IH, Broers B, Boufassa F, et al. Do gender differences in CD4 cell counts matter? AIDS 1999, 13:2361-2364.
30. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001, 344:720-725.
31. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002, 29:197-202.
32. Gange SJ, Barron Y, Greenblatt RM, Anastos K, Minkoff H, Young M, et al. The Women's Interagency HIV Study Collaborative Study Group. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health 2002, 56:153-159.
33. Prins M, Hernandez Aguado IH, Brettle RP, Robertson JR, Broers B, Carre N, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997, 11:1747-1756.
34. Brugal MT, Barrio G, De LF, Regidor E, Royuela L, Suelves JM. Factors associated with non-fatal heroin overdose: assessing the effect of frequency and route of heroin administration. Addiction 2002, 97:319-327.
35. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 200, 17:1467-1471.
36. Cascade Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000, 1:224-231.
37. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999, 13:2547-2554.
38. Porter K, Johnson AM, Philips AN, Darbyshire JH. The practical significance of potential biases in estimates of the AIDS incubation periods distribution in the UK Register of HIV Seroconverters. AIDS 1999, 13:2547-2554.